💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Imatinib

CHEMBL941 Phase 4 Approuvé Small molecule
Half-Life
18 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
493.6 g/mol
LogP
3.5
Phase
4

This oral targeted cancer therapy works by inhibiting specific tyrosine kinase enzymes, particularly BCR-ABL, the abnormal protein produced by the Philadelphia chromosome in chronic myeloid leukemia (CML). It was a breakthrough in cancer treatment and is also used for gastrointestinal stromal tumors (GISTs) and other cancers driven by specific kinase mutations. It transformed CML from a frequently fatal disease to one often managed long-term.

Masse moléculaire

493,6030 g/mol

LogP

3,50

TPSA

86,30 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Lymphoma Hypertension Breast Cancer Malaria Tuberculosis Prostate Cancer Colorectal Cancer Leukemia

Classes de médicaments

L — L - Antineoplastic and Immunomodulating Agents

Mécanisme d'action

Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.

Pharmacokinetics (PK)

Half-Life 18 hours

Pharmacodynamics (PD)

Mécanisme

Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1

                

                

                
                

                    
InChI

                    
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)

                

                

                

                    
                    

                        
Molecular Formula

                        
C29H31N7O

                    

                    
                    

                        
HBD / HBA

                        
2 / 7

                    

                    
                    

                        
Liaisons Rotatives

                        
7

                    

                    
                    
                    

                        
Atomes Lourds

                        
37

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
This oral targeted cancer therapy works by inhibiting specific tyrosine kinase enzymes, particularly BCR-ABL, the abnormal protein produced by the Philadelphia chromosome in chronic myeloid leukemia (CML). It was a breakthrough in cancer treatment and is also used for gastrointestinal stromal tumors (GISTs) and other cancers driven by specific kinase mutations. It transformed CML from a frequently fatal disease to one often managed long-term.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Imatinib: Half-life: 18 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Imatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Methotrexate
                            Small molecule
                        
                        
                        
                            Tamoxifen
                            Small molecule
                        
                        
                        
                            Cyclosporine
                            Protein
                        
                        
                        
                            Tacrolimus
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL941.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5291.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.